CTSB and cancer: TMC-52A has been identified as a cysteine protease inhibitor (Isshiki et al., 1998), while Muscimol functions as a GABAA receptor agonist (Johnston, 2014), however, the remaining compounds have no previous biological documentation concerning cancer or KIFC1.